Sep 19th, 2020 - Abstract submission categories Basic science Biliary tract cancer, incl. cholangiocarcinoma Biomarkers (agnostic) Breast cancer, early stage Breast cancer, locally advanced Breast cancer, metastatic CNS tumours Colorectal cancer Developmental therapeutics Endocrine tumours Genitourinary tumours, prostate Genitourinary tumours, non-prostate Gynaecological cancers Haematological mal...
Jul 7th, 2020 - Studies presented during the ASCO2020 Virtual Scientific Program showed the benefit of validated selection tools in pursuing surgical measures for ovarian cancer relapse, Ursula A. Matulonis, MD, of Dana Farber Cancer Institute, told Healio.
Clinical Infectious Diseases; Monica Fung MD, MPH et. al.
Jun 27th, 2020 - The coronavirus disease 2019 (COVID-19) pandemic caused by SARS coronavirus 2 (SARS-CoV-2) has caused significant morbidity and mortality for patients and stressed healthcare systems worldwide. The clinical features and outcomes of COVID-19 among immunosuppressed patients, who are at presumed risk for more severe disease but who may also have decreased detrimental inflammatory responses, are no...
Jun 25th, 2020 - The ASCO20 Virtual Scientific Program featured a variety of important and innovative breast cancer research. The following are some of the studies with potential to significantly impact clinical practice and patient outcomes, as selected by ASCO Daily News Expert Panel member Arielle Heeke, MD, of the Levine Cancer Institute.
Jun 2nd, 2020 - Genetic testing for cancer risk can significantly improve the prevention or treatment of hereditary cancers, but studies have shown that people who might have a genetic risk often don't get tested. A collaborative team of researchers have tested a possible solution through a clinical trial aimed at making genetic testing more accessible. The trial, called MAGENTA (Making GENetic Testing Accessi...
May 31st, 2020 - We are recapping some of the top news that have been presented during the conference—and soon we’ll speak with Drs Brian Rini and Christopher Sweeney on some significant data being presented in genitourinary cancers, as well as Dr Roy Herbst on some practice-changing lung cancer studies.
May 30th, 2020 - David R. Wise, MD, PhD, of New York University Perlmutter Cancer Center, summarizes three important studies in prostate cancer: circulating tumor cell count as a prognostic marker of PSA response and progression in metastatic castration-sensitive disease; new phenotypic subtypes; and how circulating tumor DNA dynamics associate with treatment response and radiologic progression-free survival (A...
May 30th, 2020 - We are recapping some of the top news that have been presented during the conference—and soon we’ll speak with Dr Melissa Johnson on some of the practice-changing lung cancer data being presented, Dr Milind Javle on some pivotal gastrointestinal cancer abstracts, and Dr Hope Rugo on the biggest studies in breast cancer.
May 30th, 2020 - Data from 2 phase 2 trials involving fam-trastuzumab deruxtecan-nxki (Enhertu) revealed the agent’s ability to induce responses in patients with HER2-positive metastatic colorectal cancer (CRC) and advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma. Both studies had results presented at the 2020 ASCO Virtual Scientific Program.
May 30th, 2020 - Men with nonmetastatic castration-resistant prostate cancer (nmCRPC) lived significantly longer if they received an androgen signaling inhibitor (ASI) in addition to conventional androgen deprivation therapy (ADT), three large randomized trials of different drugs showed.
May 29th, 2020 - Two studies presented during the ASCO20 Virtual Scientific Program show the potential to de-escalate chemotherapy in the setting of dual HER2 blockade for patients with HER2-positive breast cancer.
May 13th, 2020 - Two independent studies to be presented during the ASCO20 Virtual Scientific Program found that targeted interventions for caregivers of patients with cancer and survivors of cancer improve caregiver anxiety, distress, and self-efficacy.
May 13th, 2020 - Despite robust efforts, no adjuvant systemic therapy has succeeded in prolonging overall survival beyond that achieved with surgery alone in patients with nonmetastatic renal cell carcinoma (RCC). The phase III PROSPER RCC trial, along with similar studies, may well break that trend, ousting postsurgical surveillance as the current standard of care (Abstract TPS5101)
The Lancet Respiratory Medicine;
Mar 26th, 2020 - Lei Fang and colleagues1 suggest that clinicians should consider withholding angiotensin converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) because of a potential increased risk of worse clinical outcomes in patients with coronavirus disease 2019 (COVID-19), and they suggest calcium channel blockers as an alternative. The hypothesis behind this suggestion is that the e...
Neurology and Preclinical Neurological Studies;
Jul 3rd, 2018 - Symptoms of Parkinson’s disease have been controlled with levodopa for many years; however, motor complications consisting of wearing off of medication effect and dyskinesias tend to occur within a few years of starting levodopa. Motor complications can begin a few months after taking levodopa, with the average time to onset estimated to be 6.5 years. Dyskinesias can be troublesome and require ...
Apr 17th, 2017 - Data from two Phase 3 clinical studies investigating the efficacy and safety of ADS-5102 in Parkinson’s disease (PD) patients with levodopa-induced dyskinesia (LID) were pooled to summarize results for the shared primary endpoint, Unified Dyskinesia Rating Scale (UDysRS) and its sub-components.
Clinical Rheumatology; Queiro
Mar 27th, 2019 - High blood pressure (HBP) is a common comorbidity in psoriatic disease. Some studies indicate a higher prevalence of HBP among arthritis patients, in relation to psoriasis alone, within the psoriatic spectrum. Our objective was to study the prevalence of HBP in both types of patients as well as to analyse the factors associated with it.
Current Opinion in Neurobiology;
Mar 4th, 2008 - The crucial role of dopamine (DA) in movement control is illustrated by the spectrum of motor disorders caused by either a deficiency or a hyperactivity of dopaminergic transmission in the basal ganglia. The degeneration of nigrostriatal DA neurons in Parkinson's disease causes poverty and slowness of movement. These symptoms are greatly improved by pharmacological DA replacement with l-3,4-dih...
Postgraduate Medical Journal;
Jun 5th, 2007 - Levodopa is the most effective drug for treating Parkinson's disease. However, long‐term use of levodopa is often complicated by significantly disabling fluctuations and dyskinesias negating its beneficial effects. Younger age of Parkinson's disease onset, disease severity, and high levodopa dose increase the risk of development of levodopa‐induced dyskinesias (LID). The underlying mechanisms f...
The development of targeted therapeutics against the novel coronavirus disease 2019 (COVID-19) is highly desirable butmay present a challengein the foreseeable future.Adequate nutrition is a prerequisite of an optimally functioning immune system.Nutritional approaches,including the administration of food bioactives and micronutrients, may therefore have the potential to augmentimmune function a...